Live Investor briefing, page-14

Shellbell

No, I’m not concerned by the limitation of the patent claims to autologous cells. I simply mentioned this because, as you pointed out, OmniCar’s adaptability to allogeneic (off-the-shelf) T-cells has been previously mentioned by the company, so I noted this as a point of difference.

With respect to my comment on the potential challenge of inventive step, this was a reference to the opinion of the International Searching Authority.

As an aside, Shellbell, don’t let the detractors wear you down. Keep digging, keep doing your unique thing, but always maintain a leery eye. It may drag out, and it may be painful at times, but your combination of curiosity, optimism, hard work and tenacity should eventually yield rewards.